Search
Bioatla Inc
BCABAdd to Watchlist
1.300USD
0.0000.00%
Close 08-28 16:00（ET）
2.16MMarket Cap
LossP/E TTM
Bioatla Inc (BCAB) Stock Price Target & Forecast
Target Price
10.000USD+6427.42%
BCAB Analyst Recommendation Trends
In the current month, BCAB has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BCAB average Analyst price target in the last month is 10.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
BCAB Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, BCAB EPS is projected to reach -0.140 in FY2026Q3, following reported EPS of 0.272 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
-12.00
-0.20
-0.17
-0.14
Actual
-8.18
-211.23
0.27
--
Surprise
+31.84%
-105517.25%
+260.11%
--
FAQs
What is Bioatla Inc's price target?
Analysts forecast that Bioatla Inc's price target is USD 10.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 10.00.
How have Bioatla IncBCAB's recent earnings per share performed?
The market expectation was USD 0.27, while Bioatla IncBCAB's earnings per share (EPS) for the previous quarter was USD -211.23. EPS for the next quarter is expected at USD -0.14.